-+ 0.00%
-+ 0.00%
-+ 0.00%

BioArctic, Mesenkia sign research collaboration on glioblastoma antibody delivery approach

PUBT·08/19/2026 09:15:40
Listen to the news
BioArctic, Mesenkia sign research collaboration on glioblastoma antibody delivery approach
  • BioArctic signed a research collaboration with Mesenkia to develop an antibody-based treatment approach for glioblastoma.
  • Project combines BioArctic’s BrainTransporter technology with a Mesenkia antibody from its KITAIbodies platform targeting HVEM on tumor cells.
  • BioArctic will create the drug candidate; the partners plan preclinical studies to validate the concept before deciding next steps.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioArctic AB published the original content used to generate this news brief via Cision (Ref. ID: 202608190515BITN____UKPR__EN_20260819-BIT-9481-0) on August 19, 2026, and is solely responsible for the information contained therein.